Last reviewed 2026-04-20 · How we verify

Gemcitabine, Docetaxel, Capecitabine

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Fatigue
• Nausea
• Cough
• Anaemia
• Vomiting
• Diarrhoea
• Constipation
• Dyspnoea
• Arthralgia
• Headache
• Rash

Key clinical trials

• Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
• Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
• A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
• Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis (PHASE4)
• A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (PHASE3)
• A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PHASE3)
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Gemcitabine, Docetaxel, Capecitabine CI brief — competitive landscape report
• Gemcitabine, Docetaxel, Capecitabine updates RSS · CI watch RSS
• Columbia University portfolio CI